Abstract | BACKGROUND: STUDY DESIGN AND METHODS: RESULTS: Compared to those assigned to ferrous sulfate, more patients assigned to ferric carboxymaltose responded with a hemoglobin (Hb) increase of 2.0 g/dL or more (82% vs. 62%, 95% confidence interval for treatment difference 12.2-28.3, p < 0.001), more achieved a 3.0 g/dL or more increase (53% vs. 36%, p < 0.001), and more achieved correction (Hb >or= 12 g/dL) of anemia (73% vs. 50%, p < 0.001). Patients treated with ferric carboxymaltose compared to those prescribed ferrous sulfate reported greater gains in vitality and physical function and experienced greater improvement in symptoms of fatigue (p < 0.05). There were no serious adverse drug events. CONCLUSIONS:
|
Authors | David B Van Wyck, Antoinette Mangione, John Morrison, Phillip Earl Hadley, Judi A Jehle, Lawrence Tim Goodnough |
Journal | Transfusion
(Transfusion)
Vol. 49
Issue 12
Pg. 2719-28
(Dec 2009)
ISSN: 1537-2995 [Electronic] United States |
PMID | 19682342
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Ferric Compounds
- Ferrous Compounds
- Hematinics
- Hemoglobins
- Phosphates
- ferrous sulfate
- ferric carboxymaltose
- Maltose
- Potassium
- Calcium
|
Topics |
- Administration, Oral
- Adult
- Anemia, Iron-Deficiency
(drug therapy)
- Calcium
(blood)
- Female
- Ferric Compounds
(administration & dosage, adverse effects)
- Ferrous Compounds
(administration & dosage, adverse effects)
- Hematinics
(administration & dosage, adverse effects)
- Hemoglobins
(metabolism)
- Humans
- Injections, Intravenous
- Maltose
(administration & dosage, adverse effects, analogs & derivatives)
- Middle Aged
- Phosphates
(blood)
- Potassium
(blood)
- Quality of Life
- Treatment Outcome
- Uterine Hemorrhage
(drug therapy)
|